NET CANCER AWARENESS

Easily missed.

Take a closer look at neuroendocrine cancer.

Understanding RLT in NETs

ENGLISH

FRENCH

HOW WE HELP

0
FUNDING TO NET CANCER RESEARCH PROJECTS
0
ANNUAL VISITORS TO ONLINE RESOURCES
0
ANNUAL EMAIL & PHONE INQUIRIES
0
NET PATIENT EDUCATION SESSIONS
0
NET REFERENCE GUIDES DISTRIBUTED ACROSS CANADA
0
PATIENTS & CAREGIVERS ATTEND IN PERSON SUPPORT GROUPS
0
PATIENT & CAREGIVER ONLINE SUPPORT GROUP MEMBERS
0
ASSIST PATIENTS IN ADVOCATING FOR ACCESS TO TREATMENTS

NET Cancer is the FASTEST growing class of CANCER worldwide

HELP US HELP OTHERS
HELP US HELP OTHERS

NEUROENDOCRINE TUMOURS (NETs) OVERVIEW

  • Neuroendocrine tumours (NETs) are abnormal growth of cells (neoplasms) that arise from cells of the diffuse neuroendocrine system.

  • NETs are considered complex tumours because both tumor growth and hormonal function must be addressed.

  • NETs are most common in the lung or gastrointestinal system, but they can also originate in other parts of the body such as the thyroid, thymus, pancreas, adrenals, paraganglia, ovaries and testes.

  • NETs are classified as functional (produce hormones that cause symptoms), or non-functional (may or may not produce hormones and do not cause hormonal symptoms).

  • The cause of NETs is currently unknown.

NET ONE PAGE FACTS

CNETS NEWS

Update on Lutathera pCPA Negotiations for pNETs

October 27th, 2023|

One step closer to access to Lutathera for pNETs patients! The pan-Canadian Pharmaceutical Alliance (pCPA) negotiations with Advanced Accelerator Applications for Lutathera (lutetium 177 dotatate) in pNETs  concluded on 2023-10-17. Negotiation Status: Concluded with [...]

Board Recruitment Announcement

May 21st, 2023|

Are you looking for a unique leadership opportunity? Have you been yearning to put your talent in strategic thinking, financial analysis, project management, communications or policy advocacy in the service of a great cause?  Well, [...]

Somatuline Motorized Delivery Device – Press Release

April 9th, 2023|

Ipsen announces investment in new state-of-the-art electronic autoinjector for Somatuline® Autogel® / Somatuline® Depot (lanreotide) designed to improve patient experience. New electronic autoinjector is designed to improve patient experience for people living with gastroenteropancreatic neuroendocrine [...]

CNETS Board Member Awareness

November 4th, 2021|

CNETS Board Member Awareness Patient Education and Fundraising A core function of CNETS is to offer the Canadian neuroendocrine cancer community useful, impactful and informative educational resources [...]

CNETS PRIORITIES

AWARENESS

– Raise awareness of NET cancer to the general public & the medical community

– Participate in World NET Cancer Day Activities

SUPPORT

– In-person peer-led support groups meetings

– Dedicated patient email and phone support

– Online private support groups for patients & caregivers

EDUCATION

– Patient and caregiver education sessions across Canada

– Robust online patient educational resources

– Printed educational resources including the NET Reference Guide

– Annual NET Medical and Scientific Meeting

ADVOCACY

– Assist patients in advocating for access to treatments and diagnostics

RESEARCH

– Fund Canadian NET cancer research projects

Share This Page, Choose Your Platform!